A Phase 3 interventional study of PS Group and NCPAP Group in Respiratory Distress Syndrome, Newborn, sponsored by Vermont Oxford Network. Completed at 1 site in United States. Open to participants aged 26 Weeks to 29 Weeks. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by Vermont Oxford Network · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Respiratory Distress Syndrome, Newborn · United States.
Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, this one is the 3rd largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2003, is one of 3 in phase 3, and was the 6th registered.
123 studies on the registry are indexed under Respiratory Distress Syndrome, Newborn; 24 are open to participants now.
Browse Respiratory Distress Syndrome, Newborn studies →5 of the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States are open now. Recruiting first, the newest first:
Hackensack Meridian Health · Sites in United States
Ages 27 wk–34 wk
Mayo Clinic · Sites in United States
Ages 32 wk–41 wk · Healthy volunteers
Connecticut Children's Medical Center · Sites in United States
Ages 0 hrs–2 hrs
Endeavor Health · Sites in United States
Ages up to 15 min · Healthy volunteers
Keck School of Medicine of USC · Sites in United States
Ages 1 hrs–24 hrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Respiratory Distress Syndrome, Newborn studies recruiting now, 2 (17%) set no upper age limit and 10 (83%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: 26 Weeks to 29 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 4 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 648 is above the median of 90 across 93 interventional studies indexed under Respiratory Distress Syndrome, Newborn.
Median enrollment 93 across the 29 interventional studies, 500 across the 5 observational. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 34 have an industry lead sponsor. The 10 most frequent:
Vermont Oxford Network is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Vermont Oxford Network has 1 study filed under Respiratory Distress Syndrome, Newborn — fewer than ten, so there is no comparison to draw.
1 of the studies in Respiratory Distress Syndrome, Newborn with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06446453Connecticut Children's Medical CenterEchography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The best mode of delivery room stabilization for premature infants at high risk for respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk for respiratory distress syndrome.
The "Delivery room management of premature infants at high risk of respiratory distress syndrome" protocol compares three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk of respiratory distress syndrome. The three approaches to post-delivery care include:
The primary null hypothesis for this study is that no difference will be found in chronic lung disease and/or mortality at 36 weeks adjusted age in premature infants at high risk of RDS, depending on the method of post-delivery stabilization.
The study is a randomized, multicenter trial conducted at participating Vermont Oxford Network Centers. Participating centers will demonstrate competency in the use of nasal CPAP by successfully completing a web-based, educational program and utilizing nasal CPAP in a minimum of 20 infants in their NICU.
Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks will be eligible for inclusion. Specific inclusion criteria that must be met prior to randomization include:
Exclusion criteria will include:
Eligible infants will have consent obtained prior to delivery. They will be stratified into two groups: 26 + 0 to 27 + 6 weeks gestation and 28 + 0 to 29 + 6 weeks gestation. Shortly before delivery, infants will be randomized to one of the three stabilization strategies detailed below:
Infants requiring intubation for respiratory failure during this study (in any of the three groups) may be stabilized on either conventional or high-frequency ventilation. Specific criteria regarding target ranges for blood gases and indications for extubation, subsequent surfactant dosing, management of extubation, and criteria for reintubation, are all detailed in the protocol.
The primary outcome measure is chronic lung disease (defined as documented requirement for supplemental oxygen or respiratory support) or mortality at 36 weeks adjusted age. Secondary outcome measures include a variety of clinical outcomes, as well as issues regarding duration of hospital stay and other resource utilization. Long-term outcomes will be measured by a health care questionnaire at two years of age. A sample size of over 895 infants will be required to demonstrate a 25% reduction in the risk of chronic lung disease at 36 weeks adjusted age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks will be eligible for inclusion. Specific inclusion criteria that must be met prior to randomization include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
Drug: PS Group
Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
Device: NCPAP Group
Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
Drug: ISX Group
Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
Also known as: Prophylactic Surfactant Group
Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
Also known as: Nasal CPAP group
Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
Also known as: Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE.
Death or Chronic Lung Disease
Time frame: at 36 weeks postmenstrual age
Death
Time frame: 36 weeks adjusted age
| Milestone | PS Group | NCPAP Group | ISX Group |
|---|---|---|---|
| Started | 209 | 223 | 216 |
| Completed | 209 | 223 | 216 |
| Not completed | 0 | 0 | 0 |
| participants | PS Group | NCPAP Group | ISX Group |
|---|---|---|---|
| Death or Chronic Lung Disease | 76 | 68 | 62 |
| Participants | PS Group | NCPAP Group | ISX Group |
|---|---|---|---|
| Death | 15 | 9 | 15 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prophylactic Surfactant | — | 0/209 (0%) | 0/209 (0%) |
| Surfactant Extubated to nCPAP | — | 0/216 (0%) | 0/216 (0%) |
| NCPAP | — | 0/223 (0%) | 0/223 (0%) |
| Age, Categorical(Participants) | PS Group | NCPAP Group | ISX Group | Total |
|---|---|---|---|---|
| <=18 years | 209 | 223 | 216 | 648 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(weeks of gestation) | PS Group | NCPAP Group | ISX Group | Total |
|---|---|---|---|---|
| Mean | 28.0 ± 1.1 | 28.1 ± 1.3 | 28.1 ± 1.1 | 28.0 ± 1.1 |
| Sex: Female, Male(Participants) | PS Group | NCPAP Group | ISX Group | Total |
|---|---|---|---|---|
| Female | 118 | 99 | 115 | 332 |
| Male | 91 | 124 | 101 | 316 |
| Region of Enrollment(participants) | PS Group | NCPAP Group | ISX Group | Total |
|---|---|---|---|---|
| United States | 209 | 223 | 216 | 648 |
The record gives a start of Aug 2003, a primary completion of Jun 2009 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome, Newborn →
Vermont Oxford Network